The Pilot Study of Medical Device-Neuclare for Patients With Idiopathic Normal Pressure Hydrocephalus (iNPH)

Inclusion Criteria: * Adults aged 60 to 90, regardless of gender * Individuals exhibiting gait disturbances along with at least one of the following symptoms: cognitive impairment or urinary incontinence * Evans' index \> 0.3) * When the symptoms in 2) and 3) cannot be fully explained by other neurological or non-neurological diseases * Diagnosis of INPH based on the Investigator's clinical judgement based on criteria as described in the INPH Guidelines Exclusion Criteria: * Patient with pathological lesions in the brain identified by MRI * A person who is confirmed to have organic brain lesions (e.g., cerebral edema, cerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.) on a brain MRI. * Patients with metabolic disorders such as thyroid dysfunction, hyperglycemia, hypoglycemia, liver or kidney dysfunction, and long-term use of drugs that will cause cognitive decline (e.g., anticholinergic drugs) * History of psychiatric disorder other than the inclusion criteria. * A person with a severe history of cancer/tuberculosis * A person who has contact dermatitis or sensitive skin abnormalities * Patients with a high fever of 40 degrees Celsius or higher based on eardrum body temperature * A person whose bleeding is identified due to a common procedure or surgery that may affect vital signs * A person who is unable to perform MRI tests * A person with an allergic reaction to MRI contrast agents such as Definity or Gadovist. * Other cases where the investigator judged that it is difficult to participate in the study * Patient with behavioral and psychological symptoms of dementia (BPSD) that make cooperation in the clinical trial difficult * Patients with severe cognitive impairment, defined as an MMSE score of 17 or below * Patients who have undergone shunt surgery in the past year * Patients with a history of uncontrolled thyroid, liver, or kidney dysfunction * Patients taking medications that affect gait, cognition, or urinary tract function and who have had a change in medication regimen within the past 3 months. * Patients who have undergone a cerebrospinal fluid drainage test within the past 1 month.